Investment
Features
FeesSafety
Academy
More
Pluang+

Compare FTAI Aviation Ltd (FTAI) vs Novavax Inc (NVAX) Price & Performance

FTAI Aviation LtdTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

FTAI Aviation Ltd vs Novavax Inc — how do they compare? FTAI Aviation Ltd trades at $203.85 (market cap $21.93B), while Novavax Inc trades at $8.22 (market cap $1.39B). The key difference: FTAI Aviation Ltd is far larger — about 15.8× Novavax Inc's market cap, and FTAI Aviation Ltd pays a 0.7% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

FTAINVAX
Market Cap
$21.93B$1.39B
Sector
IndustrialsHealth
52-Week High
$310.04$11.19
52-Week Low
$109.92$6.22
Enterprise Value
$24.97B$890.94M
Dividend Yield
0.7%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

FTAI Aviation Ltd

FTAI Aviation trades at $205.71, down 0.25% with a bearish technical outlook despite unanimous analyst buy ratings. The company reported strong revenue growth to $2.51 billion in 2025 with 19% net margins, though recent quarters show earnings misses. Positive developments include a strategic Boeing 737-800 freighter collaboration and expansion into data center power solutions, while negative operating cash flow raises execution concerns.

The stock presents growth potential from aerospace servicing and new power segment opportunities, but faces risks from consistent earnings misses and high valuations (P/E 42.6). Institutional sentiment remains strongly positive with 100% buy ratings, though technical indicators suggest near-term pressure with support at $195.

Novavax Inc

Novavax (NVAX) trades at $8.42, down 5.5% on the day, reflecting a bearish technical trend. Despite a low P/E of 3.14 and recent earnings beats, the company reported a net loss margin of -14.73% for 2026 and negative cash flows. Analyst consensus is a 'Buy' with a $14.00 price target, but technical indicators signal selling pressure. Recent news highlights stock volatility and shareholder dissent at the AGM.

The outlook is mixed: strong valuation ratios and earnings beats offer upside potential, but persistent negative cash flow, high debt, and competitive pressures pose significant risks. Investor sentiment is cautious amid bearish technical signals and uncertain revenue sustainability beyond 2025.

Returns comparison

Trailing returns across standard periods

About FTAI Aviation Ltd

FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.

Read more on FTAI

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX